Cargando…
Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis.1 In the US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic treatment options approximately 50% of women w...
Autor principal: | Rak Tkaczuk, Katherine H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3076013/ https://www.ncbi.nlm.nih.gov/pubmed/21494397 http://dx.doi.org/10.4137/BCBCR.S5331 |
Ejemplares similares
-
Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
por: Cristofanilli, Massimo
Publicado: (2012) -
Optimizing ixabepilone treatment schedules in patients with advanced or metastatic breast cancer
por: Egerton, Nancy
Publicado: (2010) -
Management of advanced breast cancer with the epothilone B analog, ixabepilone
por: Gradishar, William
Publicado: (2009) -
Profile and potential of ixabepilone in the treatment of pancreatic cancer
por: Smaglo, Brandon G, et al.
Publicado: (2014) -
Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
por: Puhalla, Shannon, et al.
Publicado: (2008)